evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

54 questions · 58 findings · 3 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 20 · 34.5%GRADE not reported 1 · 1.7%Very low 22 · 37.9%Low 13 · 22.4%Moderate 2 · 3.4%High 0 · 0%

ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs placebo

Tardive dyskinesia: No clinically important improvement · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia

ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).

1 finding from 1 review

Buspirone vs placebo

Tardive dyskinesia: No clinically important improvement · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

ANXIOLYTIC ‐ BUSPIRONE may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).

1 finding from 1 review

Buspirone vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs placebo

Tardive dyskinesia: No clinically important improvement · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…

ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) probably leads to lower tardive dyskinesia: 1. No clinically important improvement compared with PLACEBO (moderate certainty).

1 finding from 1 review

ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs placebo

Adverse effects ‐ any adverse effect · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…

ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).

1 finding from 1 review

ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs placebo

Leaving the study early · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…

It is very uncertain whether ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) changes leaving the study early compared with PLACEBO (very low certainty).

1 finding from 1 review

ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs placebo

Tardive dyskinesia: Deterioration of symptoms · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS changes tardive dyskinesia: Deterioration of symptoms compared with PLACEBO (very low certainty).

1 finding from 1 review

FATTY ACID ‐ ETHYL‐EPA vs placebo

Adverse effects: EPS: parkinsonism measured by average ESRS change scores · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

FATTY ACID ‐ ETHYL‐EPA showed no clear difference in adverse effects: EPS: parkinsonism measured by average ESRS change… compared with PLACEBO (low certainty).

1 finding from 1 review

FATTY ACID ‐ ETHYL‐EPA vs placebo

Adverse effects: EPS: dystonia measured by average ESRS change scores · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

FATTY ACID ‐ ETHYL‐EPA showed no clear difference in adverse effects: EPS: dystonia measured by average ESRS change scores compared with PLACEBO (low certainty).

1 finding from 1 review

FATTY ACID ‐ ETHYL‐EPA vs placebo

Adverse effects: 2. Extrapyramidal ‐ akathisia · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether FATTY ACID ‐ ETHYL‐EPA changes adverse effects: EPS: akathisia measured by average ESRS change scores compared with PLACEBO (very low certainty).

1 finding from 1 review

FATTY ACID ‐ ETHYL‐EPA vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Ginkgo biloba vs placebo

Tardive dyskinesia: No clinically important improvement · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

HERB ‐ GINKGO BILOBA probably leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (moderate certainty).

1 finding from 1 review